Transgene Will Present Cancer Vaccine Data in Phoenix
The biotech firm will reveal preclinical results for its systemic oncolytic virus candidate at the upcoming SITC meeting.
Updated on Oct. 5, 2026 in Biotech
Transgene, a developer of virus-based immunotherapies for cancer, will present findings on its PoxSTG-EEV candidate at the SITC 2026 Annual Meeting in Phoenix on November 7, 2026. The presentation will detail the systemic delivery capabilities of the enveloped oncolytic virus.
Why it matters
The upcoming presentation marks a milestone for Transgene as it showcases data on a chimeric oncolytic poxvirus designed to reach tumors systemically. This development is part of a broader effort to improve the reach and efficacy of oncolytic virus-based cancer treatments.
The PoxSTG-EEV candidate utilizes an enveloped virion-based formulation to enable systemic delivery, differing from traditional local injection methods. Further technical specifications are cataloged under abstract 1050 for the 2026 Society for Immunotherapy of Cancer meeting.
The players
Transgene
A biotechnology company based in Strasbourg, France, that specializes in the design and development of virus-based immunotherapies for cancer treatment.
SITC
The Society for Immunotherapy of Cancer is a professional organization that hosts annual meetings to share advancements in the field of cancer immunology.
The details
Transgene will present a poster titled PoxSTG-EEV: a Novel Enveloped Virion-Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery. The abstract for this work will be published on the SITC website ahead of the event.
Timeline
November 3, 2026: Abstract becomes available on the SITC website.
November 4 - 8, 2026: The SITC 2026 Annual Meeting takes place in Phoenix.
November 7, 2026: Poster presentation for PoxSTG-EEV.
The Tech Race
The development of PoxSTG-EEV aligns with the broader industry effort to transition oncolytic viruses from local, intra-tumoral injection toward systemic administration. This shift aims to solve the historical limitation of reaching metastatic disease sites across the body.
While the news is currently preclinical, successful systemic delivery systems may eventually expand the availability of oncolytic therapies to patients with advanced cancers. Researchers and healthcare providers should monitor the abstract for insights into how this technology could reshape cancer treatment workflows.
The takeaway
Transgene's approach highlights a technical evolution in how viral therapies navigate the bloodstream to reach cancer sites. Future milestones will depend on how the reported preclinical data translates into human clinical trials.
Further reading
For more background on industry advancements, visit the /tech/biotech/ section.
